CD274 and neoplasm: Notably, the combination of IR and anti-PD-L1 significantly reduced tumor growth than either monotherapy (anti-PD-L1 vs. IR plus anti-PD-L1: 789.67 ± 55.86 mm3vs. 292.16 ± 102.98 mm3 on day 31, P < 0.001; IR vs. IR plus anti-PD-L1 = 697.02 ± 12.98 mm3vs. 292.16 ± 102.98 mm3 on day 31, P < 0.001) (Figure 5D).